ANDA 89369, held by ANI Pharmaceuticals. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89369 (Procainamide Hydrochloride), held by ANI Pharmaceuticals, was first approved by FDA on Aug 14, 1987, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 1987 | Original application | Approved | None posted |
| Procainamide Hydrochloride250MG · tablet, extended release;oral | Procainamide Hydrochloride | Discontinued |
| Procainamide Hydrochloride500MG · tablet, extended release;oral | Procainamide Hydrochloride | Discontinued |
| Procainamide Hydrochloride750MG · tablet, extended release;oral | Procainamide Hydrochloride | Discontinued |
| May 9, 2001 | Supplement 9Manufacturing | Approved | None posted |
| Mar 30, 1995 | Supplement 8Manufacturing | Approved | None posted |
| Jan 7, 1992 | Supplement 7Labeling | Approved | None posted |
| Jan 23, 1989 | Supplement 6Labeling | Approved | None posted |
| Nov 29, 1988 | Supplement 5Labeling | Approved | None posted |
| Aug 14, 1987 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters